Allspring Global Investments
ITOS

Allspring Global Investments’s iTeos Therapeutics ITOS Stock Holding History

Allspring Global Investments’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,776
Closed -$56K – 2528
2024
Q2 		$56K Sell
3,776
-5,991
-61% -$85.8K ﹤0.01% 1946
2024
Q1 		$133K Sell
9,767
-8,645
-47% -$94.2K ﹤0.01% 1786
2023
Q4 		$202K Buy
18,412
+17,973
+4,094% +$178K ﹤0.01% 1687
2023
Q3 		$4.81K Sell
439
-14,711
-97% -$188K ﹤0.01% 2676
2023
Q2 		$201K Sell
15,150
-2,560
-14% -$36.5K ﹤0.01% 1808
2023
Q1 		$241K Sell
17,710
-90,960
-84% -$1.63M ﹤0.01% 1773
2022
Q4 		$2.12M Buy
108,670
+39,569
+57% +$773K ﹤0.01% 1225
2022
Q3 		$1.32M Sell
69,101
-203,237
-75% -$4.68M ﹤0.01% 1363
2022
Q2 		$5.61M Buy
272,338
+98,451
+57% +$2.34M 0.01% 957
2022
Q1 		$5.59M Buy
173,887
+117,384
+208% +$4.27M 0.01% 1101
2021
Q4 		$2.63M Buy
+56,503
New +$1.88M ﹤0.01% 1415

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Allspring Global Investments's ITOS Position: Q3 2024 in Review

Allspring Global Investments sold out of iTeos Therapeutics (ITOS) in Q3 2024, closing a stake of 3,776 shares — an estimated $56K sold.

Allspring Global Investments first reported a position in ITOS in Q4 2021 and held it in 11 quarters. The position peaked at $5.61M in Q2 2022. 150 funds tracked by Wall St. Rank hold ITOS as of Q3 2024.

  • Allspring Global Investments reported no remaining iTeos Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Allspring Global Investments sold 3,776 iTeos Therapeutics shares in Q3 2024, an estimated $56K.
  • Allspring Global Investments first reported a position in iTeos Therapeutics in Q4 2021 and held it in 11 quarters.
  • Allspring Global Investments's iTeos Therapeutics position peaked at $5.61M in Q2 2022.
  • 150 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2024.

Based on Allspring Global Investments's 13F filing for Q3 2024, filed 18 Oct 2024.